Protocol Ledger

NCT03701308 · Phase II/III · ACTIVE NOT RECRUITING

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Interventional Phase II/III clinical trial protocol NCT03701308 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-28 Enrollment: 267 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03701308
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)267 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03701308
Protocol FieldVerified Registry Value
NCT IdentifierNCT03701308
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment267 participants (ACTUAL)
Registered Start Date2019-03-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI